AzN’s tozorakimab shows broad COPD efficacy; FDA priority review
Tozorakimab demonstrated significant reductions in COPD exacerbations across patient subgroups. The program has FDA priority review and is projected to peak sales exceeding $5 billion.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.